Allogene Therapeutics Inc. ALLO
$1.93
▲ +1.06% 24H
About
Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. These 'off-the-shelf' products aim to provide faster, more reliable, and scalable cell therapy options compared…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees150
TickerALLO
Statistics
Market Cap$471.3M
Revenue (TTM)$0
Net Income-$190.9M
Net Margin—
EPS$-0.87
P/E-2.20
P/S—
P/B1.67
EV/EBITDA-2.67
ROE-52.3%
Dividend Yield—
Price$1.93
Data: Twelve Data · Revenue = mcap / P/S